Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5438415 | 0.87 | XDH (0.45) | XDHPDE3BPDE3AKDM5BHPGD | |
| SCHEMBL5437609 | 0.86 | KDM4E (0.47) | XDHPDE3BPDE3AHPGDMEN1 | |
| SCHEMBL5434692 | 0.83 | KDM4E (0.56) | XDHPDE3BPDE3AHPGDHTT | |
| SCHEMBL5435513 | 0.83 | PDE4A (0.42) | HPGDHTTKMT2ANPSR1KDM4E | |
| SCHEMBL5434638 | 0.78 | MEN1 (0.47) | HPGDMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5434556 | 0.77 | ALDH1A1 (0.44) | HPGDMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL5454885 | 0.76 | BRDT (0.44) | HPGDKDM4EALDH1A1GLAGAA | |
| SCHEMBL5443099 | 0.75 | PGR (0.45) | XDHKDM5BMEN1KMT2ANPSR1 | |
| SCHEMBL5437075 | 0.74 | KDM4E (0.41) | KDM5BHPGDMEN1KMT2AKDM4E | |
| SCHEMBL6320759 | 0.73 | KDM4E (0.48) | HPGDMEN1HTTKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-02-22 | — | — | US | claimed |
| EP-1636232-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-03-22 | — | — | EP | claimed |
| WO-2004104005-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-12-02 | — | — | WO | claimed |
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-02-22 | — | — | US | disclosed |
| EP-1636232-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA Bioscience nv (BE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004104005-A2 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-12-02 | — | — | WO | disclosed |
| EP-1479682-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA Bioscience nv (BE) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043000-A1 | Immunosuppresive effects of pteridine derivatives | TPMT, FKBP5, RRP15 | XDH 1819/4885PDE3B 4022/4885PDE3A 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.